Malcolm Pike, PhD, is an Emeritus Member of the Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center (MSK).
Throughout his time at MSK, Dr. Pike led and collaborated on numerous multidisciplinary studies focused on the causes and prevention of ovarian and breast cancers. He served as principal investigator of the Multidisciplinary Ovarian Cancer Outcomes Group (MOCOG) study, a major international collaboration examining the molecular and immunological factors that influence survival in advanced stage ovarian cancer.
His research also investigated how combined oral contraceptives (COCs) reduce the risk of ovarian and endometrial cancers, including how differences in COC formulations may impact this protective effect.
In collaboration with Dr. Noah Kauff and Dr. Kay Park, Dr. Pike explored the pathology of the fallopian tube and cortical inclusion cysts, two sites now believed to be the origin of most common ovarian cancers. He also worked closely with Jonine Bernstein and colleagues in MSK’s Department of Radiology to assess whether breast MRI and contrast-enhanced mammography could utilize background parenchymal enhancement (BPE) as a predictive marker for breast cancer risk, either independently or in combination with mammographic density.